Karthik Musunuri
About
Karthik Musunuri is from Greater Philadelphia. Karthik works in the following industries: "Biotechnology Research". Karthik is currently Founder at BiotechFirst, located in Philadelphia, PA. Karthik also works as Board Member at OrthoCellix, a job Karthik has held since Jan 2025. Another title Karthik currently holds is Chief Executive Officer & Co-Founder at Avstera Therapeutics Corp.. In Karthik's previous role as a CEO & Co-Founder at Advaite, Karthik worked in until Jan 2021. Prior to joining Advaite, Karthik was a Senior Chronic Care Rep at Merck and held the position of Senior Chronic Care Rep at Greater New York City Area. Prior to that, Karthik was a Vaccine Immunization Rep at GlaxoSmithKline Pharma GmbH, based in Philadelphia, PA from Jan 2017 to Jan 2018. Karthik started working as R&D Study Management at GlaxoSmithKline Pharma GmbH in Collegeville, Pennsylvania in May 2017. From Jan 2011 to Jan 2013, Karthik was Associate Product Manager at Nuron Biotech, based in Exton, PA.
Go to finalscout.com and type Karthik Musunuri's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Karthik Musunuri's current jobs
Stealth mode think tank biotech policy org for American biotechs
Phase 3 Ready, RMAT Designated potential best in class autologous knee cartilage cell therapy.
Developing next generation oral selective HDAC6 inhibitors for obesity/metabolic disease and beyond. Novel discovery research into key transcription factors regulating metabolic disease.
The Ark Institute is a consortium of individuals and institutions representing the philanthropic, life sciences, public health, and supply chain management sectors, combining their expertise and moral determination to learn the lessons from the COVID-19 pandemic and to prepare for the inevitability of future novel disease threats to society.
Karthik Musunuri's past jobs
CEO & Co-Founder
Managed Top 5 Revenue-Generating Territory for Multi-Billion Dollar Chronic Care Franchise Led Northeast #1 in Sales Performance Targets for Diabetes Franchise (Januvia® and Steglatro®) Managed over 150 Accounts in Territory, including internal medicine, endocrinologists, oncologists and cardiologists Exceeded PPO's MoM in 2019 1on1 Meetings with Chairman & CEO to Discuss Strategy and New Ideas
Top Performer Q3 2018 for Highest Contract Conversions recognized by senior leadership Contributed to Shingrix® performance team discussions, manufacturing and supply strategy, and provided valuable insights and recommendations received by executive GSK leadership Deep understanding of immunization schedules Advanced understanding of preventative disease areas including meningococcal, hepatitis, zoster virus, tetanus, diphtheria, pertussis, rotavirus and influenza
Managed late stage Phase II/III clinical studies within respiratory and immunoinflammatory TAs
Worked for VP of Marketing and BD and developed market potential models for Nuron biotech products in major markets (including US, EU, Japan, Russia, Brazil). Participated in BD discussions with major pharmaceutical companies for partnership deals (out and in-licensing). Significant Contributions to Relonsiv® (MS Biologic) market differentiation study Identified superior auto-injector/company & partnered for Relonsiv® Lead Relonsiv® Branding Project